On Tuesday, Johnson & Johnson (NYSE: JNJ) opened higher 1.87% from the last session, before settling in for the closing price of $209.72. Price fluctuations for JNJ have ranged from $141.50 to $215.18 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 0.55% annually for the last half of the decade. Company’s average yearly earnings per share was noted 8.49% at the time writing. With a float of $2.41 billion, this company’s outstanding shares have now reached $2.41 billion.
Johnson & Johnson (JNJ) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Johnson & Johnson is 0.12%, while institutional ownership is 74.26%. The most recent insider transaction that took place on Nov 26 ’25, was worth 257,688. In this transaction Director of this company bought 1,250 shares at a rate of $206.15, taking the stock ownership to the 1,849 shares. Before that another transaction happened on Nov 26 ’25, when Company’s 10% Owner sold 6,337 for $10.03, making the entire transaction worth $63,560. This insider now owns 4,040,861 shares in total.
Johnson & Johnson (JNJ) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 2.04 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 2.01) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.53% during the next five years compared to 0.55% growth over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Check out the current performance indicators for Johnson & Johnson (JNJ). In the past quarter, the stock posted a quick ratio of 0.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.59. Likewise, its price to free cash flow for the trailing twelve months is 26.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.36, a number that is poised to hit 2.49 in the next quarter and is forecasted to reach 11.50 in one year’s time.
